Core Viewpoint - Maiwei Biotech has signed exclusive licensing and preferred stock purchase agreements with Kalexo Bio, Inc. for the 2MW7141 project, which could yield up to $1 billion in upfront and milestone payments, along with low single-digit royalties [1][2]. Group 1: Company Overview - Maiwei Biotech's stock price increased by over 10% following the announcement, reaching a peak increase of 13.21% [1]. - The company is focused on developing dual-target small nucleic acid drugs, with 2MW7141 aimed at managing dyslipidemia and preventing high-risk cardiovascular events [2][5]. - The 2MW7141 project is currently in the CMC (Chemistry, Manufacturing, and Controls) development stage, and specific drug targets have not been disclosed due to confidentiality [1][5]. Group 2: Partnership Details - The agreement with Kalexo allows for exclusive global development, production, and commercialization rights for the 2MW7141 project [2]. - Kalexo, established in December 2023, is an innovative drug company created by AditumBio, which focuses on accelerating new drug development through capital and expertise [2][3]. - The potential total transaction value for the partnership is higher than previous collaborations, with Maiwei Biotech receiving an upfront payment of $12 million and milestone payments contributing to the total of up to $1 billion [3]. Group 3: Industry Context - The cardiovascular disease sector is highly competitive, with major pharmaceutical companies actively pursuing small nucleic acid therapies [5]. - Existing therapies, while effective, still leave room for improvement in reducing disease indicators, which the dual-target approach of 2MW7141 aims to address [5]. - Recent collaborations in the industry, such as the one between Boehringer Ingelheim and Novartis, highlight the trend of strategic partnerships focusing on early-stage projects in the small nucleic acid space [5][6].

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 108.41 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 6.95 billion yuan [1] - A total of 222 stocks saw net inflows, while 366 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 175 stocks rose, with two stocks, Dekoli and Huafeng Technology, hitting the daily limit, while 408 stocks declined [1] - The top three stocks with the highest net inflows were Huafeng Technology (337 million yuan), Maiwei Biology (298 million yuan), and Zhongwei Company (220 million yuan) [1][2] Continuous Fund Flow Analysis - There are 39 stocks that have seen continuous net inflows for more than three trading days, with Hanwujing leading at 22 consecutive days of inflow [2] - Conversely, 162 stocks have experienced continuous net outflows, with Naike Equipment leading at 15 consecutive days of outflow [2] Top Fund Inflows - The top stocks by net inflow include: - Huafeng Technology: 337.30 million yuan, with a 20% increase [2] - Maiwei Biology: 298.07 million yuan, with a 13.21% increase [2] - Zhongwei Company: 219.55 million yuan, with an 11.43% increase [2] Notable Outflows - The stocks with the highest net outflows included: - Haiguang Information: 1.17 billion yuan, with a 0.46% increase [1] - Dongxin Co. and SMIC: 819 million yuan and 731 million yuan outflows, respectively [1]

Group 1 - The chemical pharmaceutical sector increased by 0.47% on September 18, with Maiwei Biotech leading the gains [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] - Notable performers in the chemical pharmaceutical sector included Maiwei Biotech, which rose by 13.21% to a closing price of 54.75, and Xinnoway, which increased by 7.07% to 51.80 [1] Group 2 - The net inflow of main funds in the chemical pharmaceutical sector was 243 million yuan, while retail funds experienced a net outflow of 18.46 million yuan [2] - The top stocks by main fund inflow included Maiwei Biotech with 319 million yuan and Borui Pharmaceutical with 214 million yuan [3] - Retail investors showed significant outflows in several stocks, including Maiwei Biotech and Borui Pharmaceutical, indicating a shift in investor sentiment [3]

Group 1 - The company Maiwei Bio announced on September 18 that it repurchased approximately 140,000 shares through centralized bidding, accounting for about 0.03% of its total share capital of approximately 400 million shares [1] - The highest price for the repurchased shares was 58.02 RMB per share, while the lowest price was 52.79 RMB per share [1] - The total amount of funds used for the repurchase was approximately 7.36 million RMB [1]

格隆汇9月18日丨迈威生物(688062.SH)公布，2025年9月18日，公司通过集中竞价交易方式首次回购公 司股份135,938股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/ 股，支付的资金总额为人民币7,361,397.22元（不含印花税、交易佣金等交易费用）。 ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-054 公司于 2025 年 9 月 17 日召开第二届董事会第二十二次会议，审议通过了《关 于调整回购股份价格上限的议案》，同意将回购股份价格上限由人民币 48.00 元/股 （含）调整为人民币 66.46 元/股（含）。具体内容详见公司于 2025 年 9 月 18 日在 上海证券交易所网站（www.sse.com.cn）上披露的《关于调整回购股份价格上限的 公告》（公告编号：2025-053）。除上述调整外，回购股份方案的其他内容不变。 二、 首次实施回购股份的情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次实施回购股份情况公告如下： 迈威（上海）生物科技股份有限公司 关于以集中竞价交易方式首次回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/27 | | --- | --- | | 回购方案实施期限 | 年 月 日~ ...

智通财经APP讯，迈威生物(688062.SH)发布公告，2025年9月18日，公司通过集中竞价交易方式首次回 购公司股份135,938股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为 52.79元/股，支付的资金总额为人民币736.14万元。 ...

迈威生物(688062.SH)发布公告，2025年9月18日，公司通过集中竞价交易方式首次回购公司股份135,938 股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/股，支付的资 金总额为人民币736.14万元。 ...

迈威生物公告，2025年9月18日，公司通过集中竞价交易方式首次回购公司股份135,938股，占公司总股 本399,600,000股的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/股，支付的资金 总额为人民币7,361,397.22元（不含印花税、交易佣金等交易费用）。本次回购股份符合相关法律法规 及公司回购股份方案的规定。 ...

Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index closing at 3852.23 points, down 0.62% and below the five-day moving average, while the total trading volume reached 23,670.80 billion yuan [1]. Group 1: Market Performance - As of the latest data, 328 A-shares have surpassed the five-day moving average, indicating a mixed performance in the market [1]. - The total trading volume in the A-share market today is reported at 23,670.80 billion yuan [1]. Group 2: Individual Stock Performance - The stocks with the highest deviation from the five-day moving average include: - 德众汽车 (Dazhong Automobile) with a deviation rate of 22.13%, experiencing a daily increase of 30.00% and a turnover rate of 30.84% [2]. - 福事特 (Fushite) with a deviation rate of 13.88%, increasing by 18.86% today with a turnover rate of 22.61% [2]. - 亿华通 (Yihua Tong) showing a deviation rate of 10.10%, up by 13.75% with a turnover rate of 13.36% [2]. - Other notable stocks with significant performance include: - 沃尔德 (World) with a deviation rate of 8.54% and a daily increase of 14.82% [2]. - 兴业科技 (Xingye Technology) with a deviation rate of 8.27% and a daily increase of 10.01% [2].